Lunai Bioworks Schedules Shareholder Vote on Second Reverse Stock Split to Avoid Nasdaq Delisting

summarizeSummary

This definitive proxy statement formalizes the company's plan to seek shareholder approval for another reverse stock split, a critical measure to regain compliance with Nasdaq's minimum bid price requirement. This follows a previous 1-for-10 reverse split in September 2025 that failed to sustain the stock price above $1.00, and a subsequent Nasdaq delisting notice. The wide proposed ratio range (1-for-3 to 1-for-30) highlights the severity of the situation and the uncertainty regarding the necessary price increase. Given the company's existing 'going concern' warning and material weakness disclosure, this move underscores significant financial and operational challenges. While intended to maintain listing, there's no assurance it will prevent delisting or that the stock price will stabilize, and the unchanged authorized share count creates substantial potential for future dilution.

check_boxKey Events

• Shareholder Meeting Scheduled for Reverse Stock Split

  A special meeting of stockholders is scheduled for May 4, 2026, to vote on an amendment to the company's Certificate of Incorporation to effect a reverse stock split.

• Proposed Reverse Stock Split Ratio

  The Board is seeking approval for a reverse stock split at a ratio in the range of 1-for-3 to 1-for-30, with the exact ratio to be determined by the Board.

• Delisting Risk Drives Proposal

  The primary reason for the proposed reverse stock split is to increase the per-share trading price to maintain the company's listing on Nasdaq, following a delisting notice received on February 6, 2026, and a prior 1-for-10 reverse split in September 2025 that failed to resolve compliance issues.

• Potential for Future Dilution

  The number of authorized shares will remain unchanged at 350,000,000, which will effectively increase the number of authorized but unissued shares available for future issuance, potentially leading to dilution.

auto_awesomeAnalysis

This definitive proxy statement formalizes the company's plan to seek shareholder approval for another reverse stock split, a critical measure to regain compliance with Nasdaq's minimum bid price requirement. This follows a previous 1-for-10 reverse split in September 2025 that failed to sustain the stock price above $1.00, and a subsequent Nasdaq delisting notice. The wide proposed ratio range (1-for-3 to 1-for-30) highlights the severity of the situation and the uncertainty regarding the necessary price increase. Given the company's existing 'going concern' warning and material weakness disclosure, this move underscores significant financial and operational challenges. While intended to maintain listing, there's no assurance it will prevent delisting or that the stock price will stabilize, and the unchanged authorized share count creates substantial potential for future dilution.